Clinical Trial Update: Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of docetaxel, estramustine, and short-term androgen withdrawal in patients with rising PSA after local treatment for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Estramustine (estramustine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Adenocarcinoma of the Prostate, Prostate Cancer | Phase 2 | Status: COMPLETED